Nargenicin compounds and uses thereof as antibacterial agents

US10144741B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Katherine Young · Metuchen, US
• David B. Olsen · Johnstown, US
• Sheo B. Singh · Tempe, US
• Jing Su · Scotch Plains, US
• Robert R. Wilkening · Maplewood, US
• James M. Apgar · Voorhees, US
• Dongfang Meng · Morganville, US
• Dann Parker · Cranford, US
• Mihir Mandal · Westfield, US
• Lihu Yang · Edison, US
• Ronald E. Painter · Piscataway, US
• Qun Dang · Westfield, US
• Takao Suzuki · Shanghai, CN

Key dates

• Filing date: Mar 2, 2018
• Grant date: Dec 4, 2018
• Expiry date: Mar 2, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F7/1804
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.